Amylyx Pharmaceuticals
PublicAmylyx Pharmaceuticals is now publicly traded
The data on this page reflects Amylyx Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 6, 2022
Last Round
Follow-on Offering
Sep 10, 2025
Total Funding Raised
$933.16M
Company Overview
Amylyx Pharmaceuticals is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative and endocrine diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Amylyx Pharmaceuticals Comparables
Compare Amylyx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PridCor Therapeutics | 69% | |
| Velvio GmbH | 57% | |
| Leal Therapeutics | 57% |
For institutional investors. Book with your work email.
Amylyx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 10, 2025 | ||||
| Follow-on Offering | Jan 10, 2025 | ||||
| Follow-on Offering | Oct 11, 2022 | ||||
| IPO | Jan 6, 2022 | ||||
| Series C | Jul 20, 2021 | ||||
Convertible Debt | Feb 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Amylyx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| Evercore ISI | Follow-on Offering, IPO |
| Bain Capital Life Sciences | Series C |
| 683 Capital Management | Series C |
| Perceptive Advisors | Series C |
| Guggenheim Securities | Follow-on Offering |
| H.C. Wainwright & Co. | Follow-on Offering, IPO |
For institutional investors. Book with your work email.
Amylyx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.